Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)
Randomized Trial of Epoetin Alfa in Patients With Advanced Non-Small Cell Carcinoma of the Lung (EPO-CAN-20)
Sponsor: Ontario Clinical Oncology Group (OCOG)
Listed as NCT00310232, this PHASE3 trial focuses on Anemia and Lung Cancer and remains terminated or withdrawn. Sponsored by Ontario Clinical Oncology Group (OCOG), it has been updated 7 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
May 2024 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — May 2024 [monthly]
Terminated PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Feb 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ontario Clinical Oncology Group (OCOG)
- Ortho Biotech, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Calgary, Canada , Edmonton, Canada , Greater Sudbury, Canada , Halifax, Canada , Hamilton, Canada , London, Canada , Montreal, Canada , Saint Catherines, Canada , Saint John, Canada , St. John's, Canada and 3 more locations